Mild cognitive impairment (MCI) signifies a transitional phase between normal aging and dementia. As the disease progresses, MCI patients face considerable challenges due to the deterioration in cognitive function, activities of daily living (ADL), and neuropsychiatric symptoms. This study aims to evaluate the evidence regarding the application of acupoint therapy in individuals with MCI based on randomized controlled trials (RCTs).
Methods:
Six databases were searched to September 25, 2025, for RCTs comparing acupoint therapy (alone or combined with nonpharmacological treatments) with health education, blank or waiting groups, sham interventions, and standard treatments (nonpharmacological treatments or oral medications). Outcomes included Montreal Cognitive Assessment (MoCA) and Mini-Mental State Examination (MMSE). Data on ADL scale, relevant biomarkers, and safety data were extracted where available. After the process of literature review and data collection, risk of bias was assessed with the Cochrane Risk of Bias 2.0. Meta-analyses were performed employing the Review Manager (version 5.4.1).
Results:
Twenty-four trials comprising 2005 patients were analyzed. Acupoint therapy improved the overall cognitive function of MCI patients (MoCA: mean difference [MD] = 1.47, 95% confidence interval [CI]: [0.95, 1.99], p < 0.00001; MMSE: MD = 1.44, 95% CI: [1.03, 1.86], p < 0.00001). MoCA and MMSE scores after acupoint therapy were significantly higher than those of health education control (MoCA: MD = 2.63, 95% CI: [1.19, 4.07], p = 0.0003; MMSE: MD = 2.83, 95% CI: [2.14, 3.51], p < 0.00001), sham control (MoCA: MD = 0.94, 95% CI: [0.18, 1.69], p = 0.01; MMSE: MD = 1.29, 95% CI: [0.51, 2.08], p = 0.001), standard nonpharmacological control (MoCA: MD = 1.42, 95% CI: [0.81, 2.03], p < 0.00001; MMSE: MD = 1.09, 95% CI: [0.79, 1.40], p < 0.00001), and oral-medication control (MoCA: MD = 0.52, 95% CI: [0.06, 0.98], p = 0.03; MMSE: MD = 0.91, 95% CI: [0.22, 1.61], p = 0.01), but no difference versus blank control (MoCA: MD = −1.10, 95% CI: [−4.58, 2.38], p = 0.54; MMSE: MD = 1.80, 95% CI: [−0.92, 4.52], p = 0.20). Auricular acupressure improved ADL scores. Biomarker changes remained nonsignificant. Only nine studies reported safety events with heterogeneous definitions, leaving the risk–benefit ratio unclear.
Conclusion:
Acupoint therapy is beneficial for cognitive function in MCI patients. Additional high-quality research is needed to provide a reliable basis for the management of MCI through acupoint therapy.
PetersenRC. Mild cognitive impairment as a diagnostic entity. J Intern Med, 2004; 256(3):183–194; doi: 10.1111/j.1365-2796.2004.01388.x
3.
BaiW, ChenP, CaiH, et al.Worldwide prevalence of mild cognitive impairment among community dwellers aged 50 years and older: A meta-analysis and systematic review of epidemiology studies. Age Ageing, 2022; 51(8):afac173; doi: 10.1093/ageing/afac173
4.
JiaL, DuY, ChuL, et al.; COAST Group. Prevalence, risk factors, and management of dementia and mild cognitive impairment in adults aged 60 years or older in China: A cross-sectional study. Lancet Public Health, 2020; 5(12):e661–e671; doi: 10.1016/S2468-2667(20)30185-7
5.
CongL, RenY, WangY, et al.Mild cognitive impairment among rural-dwelling older adults in China: A community-based study. Alzheimers Dement, 2023; 19(1):56–66; doi: 10.1002/alz.12629
6.
AlbertMS, DeKoskyST, DicksonD, et al.The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer’s disease. Alzheimers Dement, 2011; 7(3):270–279; doi: 10.1016/j.jalz.2011.03.008
van DyckCH, SwansonCJ, AisenP, et al.Lecanemab in early Alzheimer’s disease. N Engl J Med, 2023; 388(1):9–21; doi: 10.1056/NEJMoa2212948
9.
ReubenDB, KremenS, MaustDT. Dementia prevention and treatment: A narrative review. JAMA Intern Med, 2024; 184(5):563–572; doi: 10.1001/jamainternmed.2023.8522
10.
KandiahN, ChanYF, ChenC, et al.Strategies for the use of Ginkgo biloba extract, EGb 761®, in the treatment and management of mild cognitive impairment in Asia: Expert consensus. CNS Neurosci Ther, 2021; 27(2):149–162; doi: 10.1111/cns.13536
11.
IsmailZ, BlackSE, CamicioliR, et al.; CCCDTD5 participants. Recommendations of the 5th Canadian Consensus Conference on the diagnosis and treatment of dementia. Alzheimers Dement, 2020; 16(8):1182–1195; doi: 10.1002/alz.12105
12.
CummingsJ, PassmoreP, McGuinnessB, et al.Souvenaid in the management of mild cognitive impairment: An expert consensus opinion. Alzheimers Res Ther, 2019; 11(1):73; doi: 10.1186/s13195-019-0528-6
13.
ZhouXX, HuangJS, XieM, et al.Expert consensus for TCM preventive treatment of diseases: Vascular mild cognitive impairment. Chin J Inf Tradit Chin Med, 2020; 27(03):1–5.
14.
PageMJ, McKenzieJE, BossuytPM, et al.The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ, 2021; 372:n71; doi: 10.1136/bmj.n71
15.
Experts’ Common Understanding Group of Chinese Prevention and Treatment of Cognitive Dysfunction. Experts’ common understanding of Chinese prevention and treatment of cognitive dysfunction. J Neurol Neurorehabil, 2006; 3(2):98–101; doi: 10.3969/j.issn.1672-7061.2006.02.012
16.
Chinese Society of Dementia and Cognitive Impairment. Chinese expert consensus on the diagnosis and treatment of mild cognitive impairment due to Alzheimer′s disease 2024. Chin J Neurol, 2022; 55(5):421–440; doi: 10.3760/cma.j.cn113694-20240320-00172
17.
HigginsJPT, ThomasJ, ChandlerJ, et al.Cochrane Handbook for Systematic Reviews of Interventions. John Wiley & Sons: Chichester; 2024.
18.
PageMJ, MoherD, BossuytPM, et al.PRISMA 2020 explanation and elaboration: Updated guidance and exemplars for reporting systematic reviews. BMJ, 2021; 372:n160.
19.
LinL, ChuH, MuradMH, et al.Empirical comparison of publication bias tests in meta-analysis. J Gen Intern Med, 2018; 33(8):1260–1267; doi: 10.1007/s11606-018-4425-7
20.
ZhuCF, YangJ, FeiAH, et al.Influence of acupuncture-moxibustion treatment on cognition disorder. J Acupunct Tuina Sci, 2012; 10(4):218–222; doi: 10.1007/s11726-012-0607-8
21.
ZhaoL, ZhangFW, ZhangH, et al.Mild cognitive disease treated with electroacupuncture: A multi-center randomized controlled trial. Zhongguo Zhen Jiu, 2012; 32(9):779–784.
22.
SunJX, ZengH, PanL. Effects of cognitive training and acupoint massage on cognitive function of elderly patients with mild cognitive impairment. Chin Gen Pract, 2016; 19(25):3108–3111.
23.
TanTT, WangD, HuangJK, et al.Modulatory effects of acupuncture on brain networks in mild cognitive impairment patients. Neural Regen Res, 2017; 12(2):250–258; doi: 10.4103/1673-5374.200808
24.
HuangET, LiSS, ChenYQ, et al.Efficacy of acupuncture and moxibustion in treating mild cognitive impairment with “Dredging governor vessel and regulating mentality”. World Sci Technol - Mod Tradit Chin Med Mater Medica, 2019; 21(4):696–702.
25.
ZhaoLH, YuBH, NongXC, et al.Correlation between the changes of 8-isoprostaglandin F2α in serum and urine and cognitive function in patients with mild cognitive impairment and the effect of moxibustion. Chin J Gerontol, 2019; 39(15):3699–3703.
26.
ChenYQ, WuHG, YinP, et al.Tongdu Tiaoshen acupuncture method for mild cognitive impairment: A randomized controlled trial. Zhongguo Zhen Jiu, 2019; 39(11):1141–1145; doi: 10.13703/j.0255-2930.2019.11.001
27.
LiH, WangZQ, YuHK, et al.The long-term effects of acupuncture on hippocampal functional connectivity in aMCI with hippocampal atrophy: A randomized longitudinal fMRI study. Neural Plast, 2020; 2020:1–9; doi: 10.1155/2020/6389368
28.
KimJH, HanZY, ParkGC, et al.Cognitive improvement effects of electroacupuncture combined with computer-based cognitive rehabilitation in patients with mild cognitive impairment: A randomized controlled trial. Brain Sci, 2020; 10(12):984; doi: 10.3390/brainsci10120984
29.
WenXY, XieMJ, ChenSJ, et al.Effect of combined rTMS with electroacupuncture on amnestic mild cognitive impairment. Chin J Integr Med, 2020; 40(10):1192–1195.
30.
LiuQQ, ChenSJ, ShenGM, et al.Effect of electronic moxibustion on memory function in patients with amnestic mild cognitive impairment. Zhongguo Zhen Jiu, 2020; 40(4):352–356.
31.
WangHY, HuQ, YuHY, et al.Clinical effect and safety of moxibustion therapy in treatment of mild cognitive impairment: A multi-center randomized controlled trial. Acupunct Res, 2020; 45(10):851–855.
32.
ChoiY, JungIC, KimAR, et al.Feasibility and effect of electroacupuncture on cognitive function domains in patients with mild cognitive impairment: A pilot exploratory randomized controlled trial. Brain Sci, 2021; 11(6):756; doi: 10.3390/brainsci11060756
33.
ChenY, HuangWP, RenDM, et al.Effect of auricular point pressing combined with sensory integration training on cognitive function of elderly patients with mild cognitive impairment. Chin Nurs Res, 2021; 35(18):3332–3335.
34.
WangHY, LiSY, HuQ, et al.Effect of moxibustion on memory function and related serum protein markers in patients with amnestic mild cognitive impairment. Acupunct Res, 2021; 46(9):794–799.
35.
WangHY, LiSY, HuQ, et al.‘Sancai Yizhi’ moxibustion combined with ‘simultaneous multitasking’ cognitive rehabilitation model on cognitive function for treatment in patients of mild cognitive impairment: A randomized, controlled trial. Chin J Tradit Chin Med Pharm, 2021; 36(11):6884–6887.
36.
ZhangJ, HuS, LiuY, et al.Acupuncture treatment modulate regional homogeneity of dorsal lateral prefrontal cortex in patients with amnesic mild cognitive impairment. J Alzheimers Dis, 2022; 90(1):173–184; doi: 10.3233/JAD-220592
37.
MaiW, ZhangAZ, LiuQ, et al.Effects of moxa cone moxibustion therapy on cognitive function and brain metabolic changes in MCI patients: A pilot 1H-MRS study. Front Aging Neurosci, 2022; 14:773687; doi: 10.3389/fnagi.2022.773687
38.
WangL, ZhangJL, GuoCL, et al.The efficacy and safety of transcutaneous auricular vagus nerve stimulation in patients with mild cognitive impairment: A double blinded randomized clinical trial. Brain Stimul, 2022; 15(6):1405–1414; doi: 10.1016/j.brs.2022.09.003
39.
XuK, WeiYC, LiuCX, et al.Effect of moxibustion treatment on degree centrality in patients with mild cognitive impairment: A resting-state functional magnetic resonance imaging study. Front Hum Neurosci, 2022; 16:889426; doi: 10.3389/fnhum.2022.889426
40.
WangL, YiY, HuangYT, et al.The effect of acupuncture combined with repetitive transcranial magnetic stimulation on mild cognitive impairment in the elderly based on the brain-gut axis. Chin J Gerontol, 2023; 43(10):2414–2418.
41.
XuWJ, DingZC, WengH, et al.Transcutaneous electrical acupoint stimulation for elders with amnestic mild cognitive impairment: A randomized controlled pilot and feasibility trial. Healthcare (Basel), 2024; 12(19):1945; doi: 10.3390/healthcare12191945
42.
JiangP, HuF, LinM, et al.Clinical efficacy of acupuncture in the treatment of mild cognitive impairment and its impact on intestinal flora. Zhongguo Zhen Jiu, 2025; 45(7):903–907; doi: 10.13703/j.0255-2930.20240424-k00051-15
43.
YinZH, BaoQN, LiYQ, et al.Discovery of the microbiota-gut-brain axis mechanisms of acupuncture for amnestic mild cognitive impairment based on multi-omics analyses: A pilot study. Complement Ther Med, 2025; 88:103118; doi: 10.1016/j.ctim.2024.103118
44.
LawtonMP, BrodyEM. Assessment of older people: Self-maintaining and instrumental activities of daily living. Gerontologist, 1969; 9(3):179–186; doi: 10.1093/geront/9.3_Part_1.179
45.
WonCW, RhoYG, KimSY, et al.The validity and reliability of Korean Activities of Daily Living (K-ADL) scale. J Korean Geriatr Soc, 2002; 6(2):98–106.
46.
MatosLC, MachadoJP, MonteiroFJ, et al.Understanding traditional Chinese medicine therapeutics: An overview of the basics and clinical applications. Healthcare (Basel), 2021; 9(3):257; doi: 10.3390/healthcare9030257
47.
World Federation of Chinese Medicine Societies, China Association of Chinese Medicine. International clinical practice guideline of Chinese medicine amnesia (2019-10-11). World J Tradit Chin Med, 2021; 16(16):2375–2376 + 2385.
48.
ZhangH, DiwuYC, YangQ, et al.Study on the correlation between traditional Chinese medicine syndrome elements and MMSE and MoCA scores in middle-aged and elderly patients with mild cognitive impairment. Chin J Tradit Chin Med Pharm, 2024; 39(4):2021–2026.
49.
DuKR, YangSJ, WangJJ, et al.Acupuncture interventions for Alzheimer’s disease and vascular cognitive disorders: A review of mechanisms. Oxid Med Cell Longev, 2022; 2022:6080282; doi: 10.1155/2022/6080282
50.
TaoL, ZhuCF, GeHH, et al.Effects of moxibustion on Du meridian in cognitive function and plasma exosomes Aβ1-42 and lncRNA H19 in Alzheimer’s patients. Tianjin J Tradit Chin Med, 2023; 40(7):864–870.
51.
TraresK, GàoX, PernaL, et al.Associations of urinary 8-iso-prostaglandin F2α levels with all-cause dementia, Alzheimer’s disease, and vascular dementia incidence: Results from a prospective cohort study. Alzheimers Dement, 2020; 16(5):804–813; doi: 10.1002/alz.12081
52.
ParkJE, GunasekaranTI, ChoYH, et al.Diagnostic blood biomarkers in Alzheimer’s disease. Biomedicines, 2022; 10(1):169; doi: 10.3390/biomedicines10010169
53.
SunJX, ZengH, PanL. Effects of acupoint massage on cognitive functions of the elderly with mild cognitive impairment. Chin Gen Pract, 2015; 18(9):1057–1060.
54.
MiaoT, JiangTS, DongYH, et al.Effects of auricular acupuncture on the memory and the expression of ChAT and GFAP in model rats with Alzheimer’s disease. Zhongguo Zhen Jiu, 2009; 29(10):827–832.
55.
HeW, WangX, ShiH, et al.Auricular acupuncture and vagal regulation. Evid Based Complement Alternat Med, 2012; 2012:786839; doi: 10.1155/2012/786839
56.
LuanS, WilliamsI, NikolicK, et al.Neuromodulation: Present and emerging methods. Front Neuroeng, 2014; 7:27; doi: 10.3389/fneng.2014.00027
57.
GergesANH, GraetzL, HillierS, et al.Transcutaneous auricular vagus nerve stimulation modifies cortical excitability in middle-aged and older adults. Psychophysiology, 2025; 62(1):e14584; doi: 10.1111/psyp.14584
58.
ChenQY, GaoSS, GuoCL, et al.Research progress on transcutaneous auricular acupoint electrical stimulation (taVNS) for mild cognitive impairment. Chin J Alzheimers Dis Relat Disord, 2024; 7(2):142–146; doi: 10.3969/j.issn.2096-5516.2024.02.010
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
